The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of Cubist Pharmaceuticals, Inc. (“Cubist” or the “Company”)
(Nasdaq: CBST) relating to the proposed buyout of the Company by Merck &
Co., Inc. (“Merck”).
On December 8, 2014, Cubist and Merck announced the signing of a
definitive agreement pursuant to which Merck will acquire Cubist in a
transaction valued at approximately $9.5 billion.
for SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information investment picks